How can patients with these conditions improve their quality of life beyond eculizumab treatment?

SOLIRIS may lower the ability of your immune system to fight infections. • SOLIRIS increases your chance of getting serious meningococcal infections caused by ... Sep 21, 2024 ... Eculizumab is approved for atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), and myasthenia gravis. 2. How ... Apr 3, 2025 ... Eculizumab (brand names Soliris, Bkemv, Epysqli) is used to treat paroxysmal nocturnal hemoglobinuria (PNH) in adults, and a rare chronic blood ... Aug 10, 2021 ... This review presents a discussion on the therapeutic efficacy and tolerability of eculizumab in patients with MG and a summary on relevant pharmacological data. Soliris is not expected to affect the aplastic component of anaemia in patients with PNH. Meningococcal Infection. Due to its mechanism of action, the use of ... The generic drug name is eculizumab (ek-u-liz-oo-mab). Soliris® is a brand ... Eculizumab is a monoclonal antibody, a type of targeted therapy. It. Nov 18, 2022 ... Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREiHUS study Why is Soliris authorised in the EU? Soliris was shown to benefit patients with these rare diseases. The safety profile was similar for all the diseases and was ... May 3, 2019 ... In an open-label study involving 14 patients with highly clinically active, AQP4-IgG–positive disease, the use of eculizumab reduced the frequency of relapse. Jan 1, 2022 ... Soliris® (eculizumab) is unproven and not medically necessary for treatment of Shiga toxin E. coli-related hemolytic uremic syndrome (STEC-HUS).